Article
Oncology
Yu Xu, Wenjing Zhang, Tingting Xia, Yuliang Liu, Zhoukui Bi, Liang Guo, Weijia Xie, Ying Xiang, Zhi Xu, Zubin Yu, Yafei Li, Li Bai
Summary: This study confirmed the diagnostic value of 7 tumor-associated autoantibodies (AABs) for lung cancer and explored the potential improvement in diagnostic value by combining them with 7 traditional tumor-associated antigens (TAs).
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Tobias Sikosek, Rastislav Horos, Franziska Trudzinski, Julia Jehn, Maurice Frank, Timothy Rajakumar, Laura V. Klotz, Nathaniel Mercaldo, Mustafa Kahraman, Marco Heuvelman, Yasser Taha, Jennifer Gerwing, Jasmin Skottke, Alberto Daniel-Moreno, Marta Sanchez-Delgado, Sophie Bender, Christina Rudolf, Franziska Hinkfoth, Kaja Tikk, Judith Schenz, Markus A. Weigand, Peter Feindt, Christian Schumann, Petros Christopoulos, Hauke Winter, Michael Kreuter, Marc A. Schneider, Thomas Muley, Stephan Walterspacher, Martin Schuler, Kaid Darwiche, Christian Taube, Balazs Hegedus, Klaus F. Rabe, Kimberly Rieger-Christ, Francine L. Jacobsen, Clemens Aigner, Martin Reck, Alexander A. Bankier, Amita Sharma, Bruno R. Steinkraus
Summary: Lung cancer is the deadliest cancer and its survival is influenced by tumor stage. Low-dose computed tomography screening can reduce mortality but has low adherence in the US and limited implementation in Europe. Therefore, additional screening tests, such as blood tests, are needed for early detection in primary care settings.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Cuipeng Qiu, Xiao Wang, Serina A. Batson, Bofei Wang, Carlos A. Casiano, Giulio Francia, Jian-Ying Zhang
Summary: This study utilized Luminex technology to evaluate and optimize a panel of anti-tumor associated antigen (TAA) autoantibodies for prostate cancer (PCa) detection. Twelve autoantibodies showed significantly high frequencies in PCa group, and the performance of HSP60 autoantibody was confirmed using ELISA. A panel consisting of p16, IMP2, and HSP60 achieved an impressive AUC of 0.910 with high sensitivity and specificity, particularly in distinguishing Hispanic American PCa patients from normal controls.
Article
Biochemistry & Molecular Biology
Xiao Wang, Keyan Wang, Cuipeng Qiu, Bofei Wang, Xiaojun Zhang, Yangcheng Ma, Liping Dai, Jian-Ying Zhang
Summary: This study found that autoantibody to GNAS could be a potential biomarker for the early detection of HCC. The autoantibody response to GNAS in patients at different stages was closely associated with the progression of chronic liver lesions. Additionally, high positive rates of GNAS autoantibody in AFP negative and early-stage HCC patients could supplement AFP in early detection of HCC.
Review
Biochemistry & Molecular Biology
Pavel V. Belousov
Summary: Research on the analysis of circulating antibodies' antigenic specificities in cancer patients faces limitations in key conceptual and methodological aspects, but potential improvements are being discussed to enhance the detectability of pathogenetically relevant and diagnostically significant TAA.
BIOCHEMISTRY-MOSCOW
(2021)
Article
Genetics & Heredity
Maxim Pilyugin, Magdalena Ratajska, Maciej Stukan, Nicole Concin, Robert Zeillinger, Irmgard Irminger-Finger
Summary: The study found that measuring autoantibody binding to multiple epitopes of BARD1 combined with CA125 can accurately distinguish OC from healthy controls, with better results in all OC stages and menopausal status.
Article
Oncology
Karlijn de Joode, Sharon Veenbergen, Claudia Kransse, Dian Kortleve, Reno Debets, Ron H. J. Mathijssen, Arjen Joosse, Marco W. J. Schreurs, Astrid A. M. van der Veldt
Summary: A study showed that the presence of tumor-associated antibodies correlated with response to immune checkpoint inhibitor treatment in patients with metastatic melanoma. However, a new study failed to validate and extend these findings and did not identify other cancer germline antigens as predictive biomarkers of response to immune checkpoint inhibitors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Renren Ouyang, Shiji Wu, Bo Zhang, Ting Wang, Botao Yin, Jin Huang, Wei Wei, Min Huang, Minxia Zhang, Yun Wang, Feng Wang, Hongyan Hou
Summary: The study found that combining tumor-associated antigens (TAAs) and autoantibodies improved the diagnostic performance for lung cancer, particularly in early detection, showing potential for critical value in screening and early diagnosis.
Article
Neurosciences
Cassandra A. DeMarshall, Jeffrey Viviano, Sheina Emrani, Umashanger Thayasivam, George A. Godsey, Abhirup Sarkar, Benjamin Belinka, David J. Libon, Robert G. Nagele
Summary: This study demonstrates that blood-based autoantibodies can accurately and non-invasively detect AD-related pathology, especially in the pre-symptomatic and mild cognitive impairment stages. The results suggest that autoantibodies could serve as an accurate, inexpensive, and accessible diagnostic tool to aid clinicians in diagnosing Alzheimer's disease.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Review
Biochemistry & Molecular Biology
Mengtao Xing, Xinzhi Wang, Robert A. Kiken, Ling He, Jian-Ying Zhang
Summary: Early detection and treatment of HCC are crucial for improving patient survival rates. Discovering specific biomarkers and understanding the immunological mechanisms are urgent, with the immune system playing a key role in the recognition and targeted therapy of HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Jamie E. Medina, Nicholas C. Dracopoli, Peter B. Bach, Anna Lau, Robert B. Scharpf, Gerrit A. Meijer, Claus Lindbjerg Andersen, Victor E. Velculescu
Summary: This study evaluates progress in early cancer detection tests and discusses the challenges in demonstrating their clinical utility before implementing them into routine clinical care.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Ezequiel Dantas, Anirudh Murthy, Tanvir Ahmed, Mujmmail Ahmed, Shakti Ramsamooj, Maurice A. Hurd, Tiffany Lam, Murtaza Malbari, Christopher Agrusa, Olivier Elemento, Chen Zhang, Darryl J. Pappin, Timothy E. McGraw, Brendon M. Stiles, Nasser K. Altorki, Marcus D. Goncalves
Summary: The study found that TIMP1 is a suitable biomarker for early detection of lung cancer, and high expression is associated with poor prognosis.
CLINICAL AND TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Xiaoyan Sun, Weiran Liu, Leina Sun, Huilan Mo, Yingnan Feng, Xinyi Wu, Chenguang Li, Chen Chen, Jingjing Li, Ying Xin, Zhenfa Zhang, Changli Wang, Bin Zhang, Dongsheng Yue
Summary: This study investigated the maturation and abundance of tertiary lymphoid structures (TLS) in resectable non-small cell lung cancer (NSCLC) patients receiving neoadjuvant treatments, and found that the maturation of TLS is associated with treatment response and patient prognosis. The neoadjuvant chemoimmunotherapy group showed the highest TLS maturation and abundance, as well as higher rates of major pathological response (MPR) and pathological complete response (pCR). The maturation and abundance of TLS were significantly correlated with MPR and disease-free survival (DFS), and were independent predictors for DFS.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Ning Li, Van K. Holden, Janaki Deepak, Nevins W. Todd, Feng Jiang
Summary: This study identified TAs and TAAbs in sputum as potential biomarkers for early detection of lung cancer through molecular analysis. Three sputum TAAbs against DDX6, ENO1, and 14-3-3 zeta were developed as biomarkers with 81% sensitivity and 83% specificity for the diagnosis of lung cancer.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Hiroyuki Katayama, Makoto Kobayashi, Ehsan Irajizad, Alejandro Sevillarno, Nikul Patel, Xiangying Mao, Leona Rusling, Jody Vykoukal, Yining Cai, Fuchung Hsiao, Chuan-Yih Yu, James Long, Jinsong Liu, Franscisco Esteva, Johannes Fahrmann, Sam Hanash
Summary: The study found that PADI2 is highly expressed in various cancer types, especially in breast cancer. The expression of PADI2 in breast tumor tissues was positively correlated with peptidyl-citrulline staining. PADI2 expression showed strong positive correlations with a B cell immune signature and MHC-II-bound citrullinated peptides.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)